Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equecabtagene autoleucel versus standard of care for lenalidomide-refractory relapsed/refractory multiple myeloma
ChiCTR2400084921Phase 3Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of equecabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Progression-free survival. Started May 2024; status: recruiting.
02
Drugs
equecabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2400084921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084921.